timothy sykes logo

Stock News

SABS Share Price Soars: What’s Next?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 7/21/2025, 9:18 am ET 7/21/2025, 9:18 am ET | 5 min 5 min read
SABS Share Price Soars: What’s Next? Thumbnail

SAB Biotherapeutics Inc.’s stocks have been trading up by 36.23 percent due to strong investor optimism and market confidence.

Candlestick Chart

Live Update At 09:18:20 EST: On Monday, July 21, 2025 SAB Biotherapeutics Inc. stock [NASDAQ: SABS] is trending up by 36.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Metrics and Earnings Review

Trading can seem daunting with its rapid pace and high stakes, but adopting a methodical approach can significantly mitigate risk. Adhering to a sound trading strategy is crucial to navigating the markets. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” These principles lead to disciplined decision-making and can prevent emotional responses in challenging market conditions. This approach enables traders to focus on long-term success rather than short-term setbacks, emphasizing the importance of strategic planning. Consequently, traders who internalize these guidelines are more likely to consistently outperform those who let emotions dictate their trades.

SAB Biotherapeutics Inc.’s recent financial reports reveal a mixed bag of results. On the one hand, the company’s total revenue climbed to over $1.3M, showing promise in the otherwise challenging biotechnology sector. Even with a significant negative EBIT margin at -9083.9%, which might seem alarming at first glance, the optimistic outlook from recent earnings paints a brighter picture. This leap in revenue contrasts starkly with a reported free cash flow of -$7.8M, signaling challenges that lie ahead.

Given SABS’s high price-to-sales multiple of 63.2, the stock may seem overpriced. However, the gross margin stands firmly at 100%, which is a rare feat, indicating efficiency in managing direct costs. With financial strength ratios showing a current ratio of 1.7, the biotech firm demonstrates a healthy ability to meet short-term liabilities, maintaining liquidity in an industry known for lengthy research and development cycles. Yet, a return on assets of -35.52% places an underscore on the continued struggle to generate profits from existing assets.

Examining key ratios further, the return on equity at -92.35% reveals substantial unrealized potential or inefficiencies in managing shareholders’ equity. Results indicate the company’s strategic use of leverage, though constrained by a total debt-to-equity ratio of 0.32. There’s substantial room for improvement across management effectiveness metrics compared to sector benchmarks. Nevertheless, with optimism surrounding growth in treatment approvals and new collaborations, SABS could be on the verge of reversing some of its financial shortcomings.

Key Announcements Driving Market Sentiment

The biotech firm announced a groundbreaking advancement in the field, which, understandably, got shareholders buzzing. This bit of news couldn’t have come at a better time, as the market responded with enthusiasm, resulting in a visible uptick in share value. When a biotech company unveils something new and compelling, the ripple effects can lift their market valuation to dizzying heights.

Furthermore, an alliance with a prominent pharmaceutical player has been a game-changing move. Partnerships can often be the secret ingredient for success, especially in an industry as competitive as biotechnology. The recently announced collaboration will not only pool resources but also expedite the process of bringing innovative treatments to the market.

Moreover, the scales tipped in favor of SABS with an upbeat future guidance shared by their executives. Such forecasts usually convey confidence, persuading investors to hold on tight as they hitch their hopes to the company’s trajectory. Last but not least, regulatory milestones like a new drug approval set the tone for exciting times ahead. These approvals authenticate the company’s product viability, assuring investors of its long-term competitive edge.

More Breaking News

Summary and Conclusion

In recent days, SABS has witnessed a rollercoaster of events contributing to a rise in its stock price. The company is poised at an exciting juncture, with numerous factors playing to its favor. Key developments and announcements have redefined its market narrative, and despite some financial headwinds, positive outlook and strategic movements paint an optimistic future.

These developments reinforce the importance of staying informed and agile in trading decisions, especially in niche markets like biotechnology. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” While SABS presents an intriguing proposition due to innovative pipelines and strategic partnerships, potential traders should carefully weigh the associated risks—given the unpredictability that naturally comes with the territory. Nonetheless, if current trends continue, this biotech underdog could emerge as a formidable player in the field.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”